MOTS-c Legal Status, FDA 503A Category, and Compounding Access

Start here

Here is the MOTS-c legal status in plain words. MOTS-c is not an FDA-approved medicine, and it is not a dietary supplement — it is a research chemical. But its standing is actively in motion: the FDA has scheduled MOTS-c for discussion at a public advisory-committee meeting on July 23–24, 2026, where it sits on the agenda as a substance "being considered for inclusion" on a list that governs pharmacy compounding. That is a meeting on the calendar, not a ruling. Nothing about its status has changed yet. This page explains the rules that decide compounded access, and exactly where MOTS-c sits inside them today.

The Current Legal Status of MOTS-c

MOTS-c — a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA region — is a research peptide and is not an FDA-approved drug for any indication. It is sold only for laboratory research, with no approved human indication, formulation, or dosing.

Under the U.S. Federal Food, Drug, and Cosmetic Act, a bulk drug substance may be used in 503A pharmacy compounding only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list ^[16]. Substances not yet on that list are evaluated by FDA through a public nomination process, informed by the Pharmacy Compounding Advisory Committee (PCAC) ^[16].

MOTS-c is one of the bulk drug substances FDA has scheduled for PCAC evaluation ^[18]. Being under evaluation is not the same as being on the bulks list, and it is not the same as being approved for compounding. The audited regulatory reference this page draws on assigns no 503A numbered "Category" to MOTS-c; its present-tense status is simply that it is a research peptide, not FDA-approved, and scheduled for PCAC evaluation.

Named on the July 2026 FDA Advisory-Committee Agenda

The forward-leaning fact, stated carefully: MOTS-c is individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23–24, 2026, as a bulk drug substance "being considered for inclusion on the 503A Bulks List" ^[18]. FDA's calendar lists it for evaluation in both its free-base and acetate forms, and the same agenda also lists BPC-157, TB-500, and KPV ^[18].

What that means — and does not mean — matters. A scheduled PCAC discussion is a step in FDA's evaluation, not a final listing decision ^[16]. It is advisory: the committee discusses, and FDA decides separately through rulemaking ^[16]. So this is a scheduled evaluation only — not a listing decision, not a reclassification, and not a change in MOTS-c's current status. Access may expand if the process eventually moves that way, but no outcome has occurred, and none should be assumed or dated. There is no FDA-confirmed reclassification of MOTS-c on the record as of mid-2026.

The 503A and 503B Compounding Framework

Two sections of federal law govern drug compounding. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies, federal facilities, and licensed physicians, generally pursuant to a valid prescription for an individual patient ^[16]. Section 503B covers registered "outsourcing facilities" that may compound larger batches under cGMP-style oversight and FDA registration and inspection ^[16].

The pivotal rule is about ingredients. A compounder may use a bulk drug substance — an active pharmaceutical ingredient used as a starting material, rather than an FDA-approved finished drug — only if that substance has an applicable USP/NF monograph, is a component of an FDA-approved drug, or is on the applicable FDA bulks list ^[16]. Within FDA's interim policy, nominated substances were sorted into categories, and a substance FDA flagged for significant safety risks (a Category 2 substance) is not eligible for routine 503A compounding while that status stands ^[17]. FDA approval of a finished drug is a separate question from whether a bulk substance may be used in compounding; MOTS-c is not an FDA-approved drug ^[16].

Is MOTS-c a Supplement?

No — and this is a common point of confusion, so it is worth stating flatly. There is no such thing as a legal MOTS-c supplement: MOTS-c is not a dietary supplement, and it is not an FDA-approved drug either ^[16]. It is a research chemical, sold for laboratory use. Dietary-supplement marketing rules (which cover vitamins, minerals, botanicals, and certain other ingredients) do not apply to it, and it carries no approved drug status. That dual exclusion — not a supplement, not an approved drug — is the core of its access picture, and it is why the compounding framework above, rather than supplement law, is the relevant lens for any lawful access ^[16].

How Legally Compounded Peptide Access Works

In general terms, a legally compounded medication in the U.S. is prepared only after an individual patient is evaluated by a licensed prescriber who determines a compounded preparation is appropriate and issues a valid, patient-specific prescription ^[16]. The preparation is then made by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger volumes, by an FDA-registered 503B outsourcing facility ^[16].

The sequence is: a licensed-prescriber evaluation — which may begin through telehealth as a front-end consultation channel — leads to a valid prescription, which is filled by a 503A pharmacy or sourced from a 503B facility ^[16]. Telehealth is a route to that prescriber evaluation, not a separate legal status; it does not expand which substances may be compounded and does not remove the need for a legitimate clinical evaluation and a valid prescription ^[16]. And the ingredient-eligibility caveat governs throughout: a substance FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands ^[17].

This page is general information about the regulatory landscape. It is not medical or legal advice, and it is not an offer to sell or supply any substance. It names no pharmacy, clinic, telehealth provider, or vendor, and it provides no dosing or administration instructions.

Anti-Doping Status in Sport

Separately from the FDA framework, MOTS-c is treated as a prohibited substance in elite sport. Anti-doping authorities such as USADA and WADA classify it among peptide and metabolic-modulator agents prohibited at all times, and athlete use can result in sanctions. This is an anti-doping classification governing competition, distinct from the FDA compounding question above, and it is one more reason the access picture for MOTS-c is narrow rather than open. The published findings that drive interest in the compound are summarized under MOTS-c metabolic research.